Edwards Lifesciences (EW) Asset Writedowns and Impairment (2018 - 2026)
Edwards Lifesciences (EW) posted Asset Writedowns and Impairment of $40.0 million for Q2 2026, down 67.64% on a QoQ basis from $123.6 million in Q1 2026, and down 15.07% year-over-year from $47.1 million in Q2 2025.
Powered by 
Analysis
Edwards Lifesciences (EW) Asset Writedowns and Impairment (2018 - 2026) Analysis & Trends
Edwards Lifesciences has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $40.0 million in Q2 2026.
- On a quarterly basis, Asset Writedowns and Impairment fell 15.07% year-over-year to $40.0 million in Q2 2026; TTM through Jun 2026 was $350.5 million, a 644.16% increase from a year earlier, with the FY2025 full-year figure at $186.9 million, changed N/A from the prior year.
- Asset Writedowns and Impairment was $40.0 million for Q2 2026 at Edwards Lifesciences, down from $123.6 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $146.9 million in Q4 2025, with the low at $40.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | Zimmer Biomet Holdings | 18.20 Bn | 17.79 Bn | 1.54 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 40.00 Mn |
| Mar 31, 2026 | 123.60 Mn |
| Dec 31, 2025 | 146.90 Mn |
| Sep 30, 2025 | 40.00 Mn |
| Jun 30, 2025 | 47.10 Mn |
| Sep 30, 2019 | 26.90 Mn |
| Jun 30, 2019 | 46.20 Mn |
| Dec 31, 2018 | 118.80 Mn |